Literature DB >> 20822324

The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting.

Sarah Adler1, Gerd Bicker, Hans Bigalke, Christopher Bishop, Jörg Blümel, Dirk Dressler, Joan Fitzgerald, Frank Gessler, Heide Heuschen, Birgit Kegel, Andreas Luch, Catherine Milne, Andrew Pickett, Heidemarie Ratsch, Irmela Ruhdel, Dorothea Sesardic, Martin Stephens, Gerhard Stiens, Peter D Thornton, René Thürmer, Martin Vey, Horst Spielmann, Barbara Grune, Manfred Liebsch.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20822324     DOI： 10.1177/026119291003800401

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN： 0261-1929            Impact factor:   1.303


× No keyword cloud information.
  21 in total

1.  Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.

Authors:  Million Adane Tegenge; Helge Böhnel; Frank Gessler; Gerd Bicker
Journal:  Cell Mol Neurobiol       Date:  2012-02-29       Impact factor: 5.046

Review 2.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

Review 3.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

4.  Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons.

Authors:  Sabine Pellett; William H Tepp; Eric A Johnson; Dorothea Sesardic
Journal:  J Pharmacol Toxicol Methods       Date:  2017-04-29       Impact factor: 1.950

5.  Alternatives to animal testing: current status and future perspectives.

Authors:  Manfred Liebsch; Barbara Grune; Andrea Seiler; Daniel Butzke; Michael Oelgeschläger; Ralph Pirow; Sarah Adler; Christian Riebeling; Andreas Luch
Journal:  Arch Toxicol       Date:  2011-08       Impact factor: 5.153

6.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

7.  Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay.

Authors:  Ester Fernández-Salas; Joanne Wang; Yanira Molina; Jeremy B Nelson; Birgitte P S Jacky; K Roger Aoki
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

8.  Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples.

Authors:  Stéphanie Simon; Uwe Fiebig; Yvonne Liu; Rob Tierney; Julie Dano; Sylvia Worbs; Tanja Endermann; Marie-Claire Nevers; Hervé Volland; Dorothea Sesardic; Martin B Dorner
Journal:  Toxins (Basel)       Date:  2015-11-26       Impact factor: 4.546

9.  Generation and Characterization of Six Recombinant Botulinum Neurotoxins as Reference Material to Serve in an International Proficiency Test.

Authors:  Jasmin Weisemann; Nadja Krez; Uwe Fiebig; Sylvia Worbs; Martin Skiba; Tanja Endermann; Martin B Dorner; Tomas Bergström; Amalia Muñoz; Ingrid Zegers; Christian Müller; Stephen P Jenkinson; Marc-Andre Avondet; Laurence Delbrassinne; Sarah Denayer; Reinhard Zeleny; Heinz Schimmel; Crister Åstot; Brigitte G Dorner; Andreas Rummel
Journal:  Toxins (Basel)       Date:  2015-11-26       Impact factor: 4.546

10.  Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN).

Authors:  Hans Bigalke; Andreas Rummel
Journal:  Toxins (Basel)       Date:  2015-11-25       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.